Literature DB >> 2643036

De novo and salvage biosynthesis of pteroylpentaglutamates in the human malaria parasite, Plasmodium falciparum.

J Krungkrai1, H K Webster, Y Yuthavong.   

Abstract

Plasmodium falciparum was shown to synthesize pteroylpolyglutamate de novo from guanosine 5'-triphosphate (GTP), p-aminobenzoate (PABA), and L-glutamate (L-Glu). The parasite also had the capacity to synthesize pteroylpolyglutamate from both intact and degradation moieties (p-aminobenzoylglutamate and pterin-aldehyde) of exogenous folate added into the growth medium. The major product was identified as 5-methyl-tetrahydroteroylpentaglutamate following exposure to pteroylpolyglutamate hydrolase and oxidative degradation of the C9-N10 bond in the molecule and identification of products by reversed-phase high performance liquid chromatography. Inhibition of pteroylpentaglutamate synthesis from the radiolabelled metabolic precursors (GTP, PABA, L-Glu) and folate by the antifolate antimalarials, pyrimethamine and sulfadoxine at therapeutic concentrations, may suggest the existence of a unique biosynthetic pathway in the malaria parasite.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2643036     DOI: 10.1016/0166-6851(89)90126-6

Source DB:  PubMed          Journal:  Mol Biochem Parasitol        ISSN: 0166-6851            Impact factor:   1.759


  21 in total

Review 1.  Comparative folate metabolism in humans and malaria parasites (part II): activities as yet untargeted or specific to Plasmodium.

Authors:  Alexis Nzila; Steve A Ward; Kevin Marsh; Paul F G Sims; John E Hyde
Journal:  Trends Parasitol       Date:  2005-07

2.  Plasmodium falciparum: a paradigm for alternative folate biosynthesis in diverse microorganisms?

Authors:  John E Hyde; Sabine Dittrich; Ping Wang; Paul F G Sims; Valérie de Crécy-Lagard; Andrew D Hanson
Journal:  Trends Parasitol       Date:  2008-09-19

Review 3.  Comparative folate metabolism in humans and malaria parasites (part I): pointers for malaria treatment from cancer chemotherapy.

Authors:  Alexis Nzila; Steve A Ward; Kevin Marsh; Paul F G Sims; John E Hyde
Journal:  Trends Parasitol       Date:  2005-06

4.  Scaling up of intermittent preventive treatment of malaria in pregnancy using sulphadoxine-pyrimethamine: prospects and challenges.

Authors:  Wellington Aghoghovwia Oyibo; Chimere Obiora Agomo
Journal:  Matern Child Health J       Date:  2011-05

Review 5.  Exploring the folate pathway in Plasmodium falciparum.

Authors:  John E Hyde
Journal:  Acta Trop       Date:  2005-04-18       Impact factor: 3.112

6.  Exploiting structural analysis, in silico screening, and serendipity to identify novel inhibitors of drug-resistant falciparum malaria.

Authors:  Tina Dasgupta; Penchit Chitnumsub; Sumalee Kamchonwongpaisan; Cherdsak Maneeruttanarungroj; Sara E Nichols; Theresa M Lyons; Julian Tirado-Rives; William L Jorgensen; Yongyuth Yuthavong; Karen S Anderson
Journal:  ACS Chem Biol       Date:  2009-01-16       Impact factor: 5.100

7.  Characterisation of the bifunctional dihydrofolate synthase-folylpolyglutamate synthase from Plasmodium falciparum; a potential novel target for antimalarial antifolate inhibition.

Authors:  Ping Wang; Qi Wang; Yonghong Yang; James K Coward; Alexis Nzila; Paul F G Sims; John E Hyde
Journal:  Mol Biochem Parasitol       Date:  2010-03-27       Impact factor: 1.759

8.  Primary structure and expression of the dihydropteroate synthetase gene of Plasmodium falciparum.

Authors:  T Triglia; A F Cowman
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

9.  Acquisition and synthesis of folates by obligate intracellular bacteria of the genus Chlamydia.

Authors:  H Fan; R C Brunham; G McClarty
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

Review 10.  Safety and toxicity of sulfadoxine/pyrimethamine: implications for malaria prevention in pregnancy using intermittent preventive treatment.

Authors:  Philip J Peters; Michael C Thigpen; Monica E Parise; Robert D Newman
Journal:  Drug Saf       Date:  2007       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.